Glenmark Pharmaceuticals has informed that, Glenmark Pharmaceuticals Inc., USA (Glenmark) today announced the launch of Methylene Blue Injection USP, 50 mg/10 mL (5 mg/mL) Single?Dose Vial. Glenmark’s Methylene Blue Injection USP is bioequivalent and therapeutically equivalent to the reference listed drug, ProvayBlue® Injection, 50 mg/10 mL (5 mg/mL), of Provepharm SAS [NDA 204630]. According to IQVIA® sales data for the 12?month period ending April 2026, the ProvayBlue® Injection, 50 mg/10 mL (5 mg/mL) market achieved annual sales of approximately $19.0 million. The company has attached media release.
3The above information is a part of company’s filings submitted to BSE.
